Letter: Dupilumab-Induced Facial Redness: Reported Outcomes after Switching to Tralokinumab

Abstract

Get full access to this article

View all access options for this article.

References

1. Jo

, Finstad

, Georgakopoulos

, et al. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021;84(5):1339–1347.

2. Beyrouti

, Deuze

, Fontas

, French Atopic Dermatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group. et al.; Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: A multicenter retrospective study. J Allergy Clin Immunol Pract. 2025;13(2):353–360.

3. Tolino

, Bianchi

, Chiricozzi

. Complete resolution of dupilumab-associated head and neck dermatitis after switch to tralokinumab. Dermatol Ther. 2024;37:e15789.

4. Schlösser

, Shareef

, Olydam

, et al. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023;48(5):510–517.

5. Watanabe

, Kamata

, Okada

, et al. Clinical outcomes of tralokinumab and lebrikizumab in Japanese atopic dermatitis patients with persistent head and neck dermatitis after long-term treatment with dupilumab: A single-center retrospective study. J Dermatol. 2026;53(3):e164–e166.